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CASE

REPORT

Improvement of necrobiosis lipoidica with
topical ruxolitinib cream after prior
nonresponse to compounded topical tofacitinib cream
Shannon Nugent, BS,a Alexandra J. Coromilas, MD,b Joseph C. English III, MD,c and Misha Rosenbach, MDb
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INTRODUCTION
Necrobiosis lipoidica (NL) is a rare, idiopathic
granulomatous disorder that classically presents as
well-circumscribed, red to yellow plaques on the
distal legs.1 The etiology of NL remains unclear, but
suggested mechanisms involve vascular disturbance
with microangiopathy or immune complex deposition. Abnormalities in collagen and impaired neutrophil migration have also been described.2
Treatment for NL is challenging, and data evaluating treatment efficacy are lacking. High-potency
topical steroids are often prescribed as first-line
treatment. Therapeutic options for refractory disease
include intralesional steroids, topical immunomodulators, topical psoralen-ultraviolet A photochemotherapy, hydroxychloroquine, or tumor necrosis
factor-alpha inhibitors. Pentoxifylline, a hemorheologic agent with anti-inflammatory properties, has
also been associated with resolution of NL.3
More recently, Janus kinase (JAK) inhibitors have
emerged as a promising therapy for granulomatous
disorders4 and NL.5-7 Herein, we describe a case of
NL with remarkable improvement after the use of
topical 1.5% ruxolitinib cream (Opzelura, Incyte
Corp) but not compounded topical tofacitinib.

CASE REPORT
A 19-year-old woman with a 5-year history of NL
on her bilateral shins presented for ongoing disease
management. Her NL was previously refractory to
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treatment with high-potency topical steroids, pimecrolimus cream, hydroxychloroquine, methotrexate,
and pentoxifylline. Physical examination showed
well-circumscribed, red to orange shiny sclerosing
plaques with areas of central atrophy on her right
medial and anterior shin and smaller plaques on her
left medial and anterior shin (Fig 1, A). The patient
was started on pentoxifylline 400 mg twice daily,
hydroxychloroquine 200 mg twice daily, and after
1 month of minimal improvement, compounded
topical tofacitinib 2.0% cream twice daily was added.
Follow-up at 3 months demonstrated partial
improvement of her lower extremity plaques.
Hydroxychloroquine was held due to a syncopal
episode, and the patient continued treatment with
compounded tofacitinib cream and pentoxifylline
with partial improvement.
After 13 months of treatment, the patient was
switched to topical ruxolitinib 1.5% cream twice
daily and continued on pentoxifylline. Follow-up at
3 months later showed dramatic improvement in the
color and size of her lower extremity plaques
(Fig 1, B).
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to understand the role of JAK-STAT signaling in NL
and to elucidate its underlying pathophysiology and
molecular pathways. These data will provide insight
about new targeted treatments for patients with
granulomatous disorders.
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Fig 1. A, Clinical image of the patient’s necrobiosis
lipoidica at initial presentation, previously treated with
multiple therapeutic modalities. B, Clinical response of the
patient’s necrobiosis lipoidica after 3 months of treatment
with topical ruxolitinib 1.5% cream and pentoxifylline.

DISCUSSION
The clinical response of this patient’s NL to
ruxolitinib expands on emerging data that JAK
inhibitors are a promising treatment for granulomatous disorders. In granulomatous disorders, cytokines recruit and activate macrophages via
JAK-signal transducer and activator of transcription
(STAT) signaling.8 JAK-STAT signaling may be constitutively activated at low levels in NL,7 and JAK
inhibition can therefore suppress immune cell activation and T-cell-mediated inflammation.8 Case reports have similarly described improvement in NL
after treatment with JAK inhibitors.5-7,9
Selective enzyme inhibition may contribute to the
differences in therapeutic response seen between
tofacitinib and ruxolitinib. Tofacitinib preferentially
inhibits JAK1 and JAK3, while ruxolitinib inhibits
JAK1 and JAK2.8 Tofacitinib’s compounded formulation may have also limited its efficacy. Poor
drug formulation uniformity and subtherapeutic doses
have been reported with compounded medications.10
JAK inhibitors are a promising treatment for
granulomatous diseases. Further research is needed
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